Skip to main content
. 2017 May 22;9:281–293. doi: 10.2147/CEOR.S129859

Table S6.

Patients’ features according to HCV treatment

Patients’ main features SOF+RBV SOF+LDP+RBV SOF+SIM+RBV PTVr/OBV+DSV+RBV SOF+DCV+RBV SOF+SIM SOF+LDP PTVr/OBV+RBV PTVr/OBV+DSV SOF+DCV p-value

n=76 n=52 n=51 n=44 n=36 n=26 n=16 n=10 n=9 n=7
Age, years 55 (51–71) 55 (52–59) 55 (52–61) 55 (51–63) 55 (52–55) 57 (51–62) 56 (51–64) 54 (51–59) 56 (51–60) 57 (54–62) 0.43
Gender (male) 55 (72.73) 41 (78.85) 38 (774.51) 32 (72.73) 31 (86.11) 8 (30.77) 13 (81.25) 7 (70.00) 4 (44.44) 4 (57.14) <0.0001
Fibrosis stage <0.0001
 1 1 (1.32) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (3.85) 1 (6.25) 0 (0.00) 1 (11.11) 0 (0.00)
 2 1 (1.32) 0 (0.00) 1 (1.96) 0 (0.00) 0 (0.00) 1 (3.85) 2 (12.50) 0 (0.00) 0 (0.00) 1 (14.29)
 3 19 (25.00) 2 (3.85) 8 (15.69) 6 (13.64) 1 (2.87) 9 (34.62) 7 (43.75) 4 (40.00) 6 (66.67) 2 (28.57)
 4 55 (72.37) 50 (96.15) 42 (82.35) 38 (86.36) 35 (97.22) 15 (57.69) 6 (37.50) 6 (60.00) 2 (22.22) 4 (57.14)
Genotype <0.0001
 1 0 (0.00) 45 (86.54) 38 (74.51) 44 (100.00) 3 (8.33) 21 (80.77) 12 (75.00) 0 (0.00) 9 (100.00) 2 (28.57)
 2 31 (40.79) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
 3 45 (59.21) 0 (0.00) 0 (0.00) 0 (0.00) 29 (80.56) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 4 (57.14)
 4 0 (0.00) 7 (13.46) 13 (25.49) 0 (0.00) 4 (11.11) 5 (19.23) 4 (25.00) 10 (100.00) 0 (0.00) 1 (14.29)
Comorbidities 37 (48.68) 39 (75.00) 27 (52.94) 22 (50.00) 24 (66.67) 4 (15.38) 7 (43.75) 2 (20.00) 2 (22.22) 4 (57.14) <0.0001
Previous treatment HCV 35 (46.05) 29 (55.77) 37 (72.55) 27 (61.36) 18 (50.00) 7 (26.92) 5 (31.25) 4 (40.00) 8 (88.89) 4 (57.14) 0.002

Note: Data are presented as median (interquartile range) for continuous variables and as frequency (%) for categorical variables.

Abbreviations: DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted paritaprevir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir.